MedTrace Logo

Effect of Acupuncture Plus Governor Vessel Moxibustion Combined With Letrozole on Live Birth in Anovulatory Infertile Women With Spleen-kidney Yang Deficiency PCOS

NCT04987632 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-08-03

No results posted yet for this study

Summary

Investigators expected to verify this hypothesis through this study:acupuncture and moxibustion combined with LE induced ovulation in Chinese anovulatory PCOS women has a higher rate of live birth than LE induced ovulation alone.

Conditions

  • PCOS
  • Infertility, Female

Interventions

DRUG

Letrozole

Letrozole, an aromatase inhibitor, is considered to be the first-line drug for ovulation induction in PCOS.

DEVICE

acupuncture

Domestic and foreign studies suggest that acupuncture and electroacupuncture can improve the menstrual cycle of PCOS and reduce the level of total testosterone; Acupuncture can regulate glucose homeostasis by stimulating the autonomic nervous system of PCOS patients. Our previous studies and a large number of literatures have proved that acupuncture can improve insulin resistance in PCOS, and acupuncture can improve the pregnancy rate in PCOS.

OTHER

Governor vessel moxibustion

It can warm the kidney, promote digestion and absorption, remove dampness and promote blood circulation

Sponsors & Collaborators

  • Qiu-ping Lin

    lead OTHER

Principal Investigators

  • naiping wang, Chief physician · Dongguan Hospital of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-03
Primary Completion
2022-12-31
Completion
2022-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04987632 on ClinicalTrials.gov